PDSB PDS Biotechnology Corp

BULLISH Impact: 5/10 8-K
Horizon days Filed Jun 2, 2026 Processed 4d 2h ago SEC 0001140361-26-023698
8-K context-dependent: Items 8.01
Latest settled — T+1d
PDSB ▼ -6.90% at T+1d
LONG call ✗ call lost -6.90% · α vs SPY -6.20% · entry $1.16 → $1.08
Next anchor: T+5d in 3d
Currently $1.02 · -12.07% from $1.16 entry
Entry anchored
Jun 2, 03:33 PM ET
via Databento tick
T+1d
-6.90%
call -6.90% · α -6.20%
$1.08
settled 3d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 25d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the deficiency matter first disclosed on February 25, 2026. This removes the immediate delisting risk from Nasdaq, a positive administrative outcome for the $64M market cap clinical-stage biotech.

Actionable Insight

The compliance notice removes a key overhang for PDSB, which had a $64M market cap and 89% analyst bullish consensus. Monitor the stock's ability to sustain above $1.00; any subsequent dip below that threshold could trigger a new 180-day cure period. No financial data or guidance was provided in this filing.

Key Facts

  • On February 25, 2026, PDSB received a Nasdaq deficiency letter for trading below $1.00 for 30 consecutive business days.
  • On June 2, 2026, Nasdaq notified PDSB that it has regained compliance with the minimum bid price requirement and closed the matter.
  • The company's common stock continues to trade on The Nasdaq Capital Market under the symbol PDSB.

Financial Impact

No direct financial figures provided; the filing resolves a delisting risk that could have forced a transfer to OTC markets, preserving Nasdaq listing and associated liquidity/premium.

listing statusliquidity

Risk Factors

  • Stock could again fall below $1.00, triggering a new deficiency process.
  • No operational or financial catalysts were disclosed; the compliance notice does not change the company's clinical-stage risk profile.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-023698
Document: 0001140361-26-023698-index-headers.html0001140361-26-023698
Document: 0001140361-26-023698.txt0001140361-26-023698
9 reports for PDSB
Performance horizon
25% Hit rate 1 of 4 directional calls best @ T+20▲ +18.28%Apr 24, 2026
Filters
Rows
Reports for PDSB — sortable, filterable
Type Now
Jun 2, 2026
4d ago
8-K
BULLISH ★ 5/10
$1.16 $1.08▼ −6.90%▼ −6.20%$1.02 (−12.07%)
May 13, 2026
24d ago
Press Release
NEUTRAL ★ 5/10
$1.33 $1.43▲ +7.52%▲ +6.74%$1.02 (−23.31%)
May 1, 2026
5w ago
8-K
BEARISH ★ 6/10
$0.9810 $1.00▼ −1.94%▼ −2.28%$1.02 (−3.98%)
Apr 27, 2026
5w ago
S-3/A
NEUTRAL ★ 4/10
$0.9300 $1.08▲ +16.13%▲ +16.61%$1.02 (+9.68%)
Apr 24, 2026
6w ago
8-K
BULLISH ★ 6/10
$0.9300 $1.08▲ +16.13%▲ +16.61%$1.02 (+9.68%)
Apr 15, 2026
7w ago
8-K
BULLISH ★ 8/10
$1.36 $1.28▼ −5.88%▼ −6.14%$1.02 (−25.00%)
Apr 15, 2026
7w ago
Press Release
BULLISH ★ 8/10
$1.36 $1.28▼ −5.88%▼ −6.14%$1.02 (−25.00%)
Mar 30, 2026
9w ago
Press Release
MIXED ★ 6/10
$0.5370 $0.6050▲ +12.66%▲ +9.77%$1.02 (+89.94%)
Mar 24, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$0.6350 $0.6400▲ +0.79%▲ +2.56%$1.02 (+60.63%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (14h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access